Complement C3 Variant and the Risk of Age-Related Macular Degeneration

A variant on complement factor 3 is associated with age-related macular degeneration, with a population attributable risk of 22%. This finding underlines the importance of complement activation in the pathogenesis of the disease. A variant on complement factor 3 is associated with age-related macula...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2007-08, Vol.357 (6), p.553-561
Hauptverfasser: Yates, John R.W, Sepp, Tiina, Matharu, Baljinder K, Khan, Jane C, Thurlby, Deborah A, Shahid, Humma, Clayton, David G, Hayward, Caroline, Morgan, Joanne, Wright, Alan F, Armbrecht, Ana Maria, Dhillon, Baljean, Deary, Ian J, Redmond, Elizabeth, Bird, Alan C, Moore, Anthony T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A variant on complement factor 3 is associated with age-related macular degeneration, with a population attributable risk of 22%. This finding underlines the importance of complement activation in the pathogenesis of the disease. A variant on complement factor 3 is associated with age-related macular degeneration, with a population attributable risk of 22%. Age-related macular degeneration is the leading cause of visual impairment in the elderly and the most common cause of blindness in Western countries. 1 It affects the macular region of the retina. The macula has a high density of photoreceptors and provides detailed central vision. In the early stages of the disease (referred to as age-related maculopathy), deposits called drusen develop between the retinal pigment epithelium and underlying choroid. 1 Later, the disease is manifested as either extensive atrophy of the retinal pigment epithelium and overlying photoreceptor cells (geographic atrophy) or aberrant choroidal angiogenesis (choroidal neovascularization). 1 Both of these conditions can lead . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa072618